Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Podobne zapisy

• Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
  od: Risueño, A, i wsp.
  Wydane: (2023)
• AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial
  od: DiNardo, CD, i wsp.
  Wydane: (2022)
• Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
  od: DiNardo, CD, i wsp.
  Wydane: (2021)
• Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
  od: De Botton, S, i wsp.
  Wydane: (2022)
• Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
  od: Dinardo, CD, i wsp.
  Wydane: (2022)